Research Article| Volume 18, SUPPLEMENT 2, 3-8, 1996

Gammagard® and reported hepatitis C virus episodes

      This paper is only available as a PDF. To read, Please Download here.


      Since first licensed in the United States in 1986, Gammagard®, an intravenous immunoglobulin produced by the Hyland Division of Baxter Healthcare Corporation, had been considered an effective and safe form of immunoglobulin. Its safety had been proved in patients with immunoglobulin A (IgA) deficiency, including those with the complication of anti-IgA antibodies. However, in early 1994, there were reported episodes of hepatitis C virus transmission associated with administration of Gammagard manufactured during April 1993 and thereafter. The investigations into the mechanisms to account for these events, including the manufacturing processes, are reviewed. The results of studies and analyses by both Baxter and the US Food and Drug Administration, including first- and second-generation enzyme-linked immunosorbent assays, polymerase chain reaction analyses, and the solvent-detergent viralinactivation manufacturing step, are discussed. Evaluations of donor histories identified a group of donors who contributed to three target lots of the agent and who were subsequently excluded from donor pools. The classification scheme and criteria for all patient reports of hepatitis associated with administration of Gammagard, as well as the classification of all hepatitis C virus episodes, are presented.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia
        Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: A randomized controlled clinical trial.
        NEJM. 1988; 319: 902-907
        • van der Meche FG
        • Schmitz PI
        • Dutch Guillain-Barré Study Group
        A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome.
        NEJM. 1992; 326: 1123-1129
        • The Intravenous Immunoglobulin Collaborative Study Group
        Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection.
        NEJM. 1992; 327: 234-240
        • Baker CJ
        • Melish ME
        • Hart RT
        • et al.
        • The Multicenter Group for the Study of Immune Globulin in Neonates
        Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates.
        NEJM. 1992; 327: 213-219
        • Lee ML
        • Courter SG
        • Tait D
        • Kingdon HS
        Long-term evaluation of intravenous immune globulin preparation with regard to non-A, non-B hepatitis safety.
        in: Zuckerman AJ Viral Hepatitis and Liver Disease. Alan R. Liss, New York1988: 596-599
        • Oomes PG
        • van des Meahe FGA
        • Kleyweg RP
        Liver function disturbances in Guillain-Barre syndrome: A prospective longitudinal study in 100 patients.
        Neurology. 1996; 46: 96-100
        • Cunningham-Rundles C
        • Zhou Z
        • Mankarious S
        • Courter S
        Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies.
        J Clin Immunol. 1993; 13: 272-278
        • Murdoch A
        Irish mothers called for hepatitis C virus screening.
        BMJ. 1994; 308: 613-614
        • Ochs HD
        • Fischer SH
        • Virant FS
        • et al.
        Non-A non-B hepatitis and intravenous immunoglobulin.
        Lancet. 1985; 1: 404-405
        • Weiland O
        • Mattsson L
        • Glaumann H
        Non-A non-B hepatitis after intravenous gamma globulin.
        Lancet. 1986; 1 (Letter): 976-977
        • Lane RS
        Non-A non-B hepatitis from intravenous immunoglobulin.
        Lancet. 1983; 2 (Letter): 974-975
        • Lever AM
        • Webster AD
        • Brown D
        • Thomas HC
        Non-A non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin.
        Lancet. 1984; 2: 1062-1064
        • Finlayson JS
        • Tankersley DL
        Anti-HCV screening and plasma fractionation: The case against.
        Lancet. 1990; 335 (Letter): 1274-1275
        • Centers for Disease Control
        Outbreak of hepatitis C associated with intravenous immunoglobulin administration: United States, October 1993–June 1994.
        MMWR. 1994; 43: 505-509